RNASEL Arg462Gln polymorphism and prostate cancer in PLCO

Sarah E. Daugherty, Richard B. Hayes, Meredith Yeager, Gerald L. Andriole, Nilanjan Chatterjee, Wen Yi Huang, William B. Isaacs, Elizabeth A. Platz

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND. The Gln allele of the Arg462Gln polymorphism in RNASEL results in a threefold decrease in enzymatic activity, a reported deficiency in apoptotic response, and has been associated with prostate cancer in some high-risk family studies. The relationship of this variant to sporadic prostate cancer remains uncertain. METHODS. We conducted a nested case-control study of 1,317 prostate cancer cases and 1,842 controls from the screening arm of the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. Conditional logistic regression was used to evaluate the association between the RNASEL Arg462Gln polymorphism and prostate cancer. RESULTS. No statistically significant association was observed between the Arg462Gln polymorphism and prostate cancer (compared to Arg/Arg, Gln/Arg: OR= 0.99 95% CI 0.84-1.16; Gln/Gln: OR= 0.95 95% CI 0.74-1.21), although slight non-significant differences in risk were observed among men with the Gln/Gln genotype by stage and grade. CONCLUSIONS. These results suggest that the RNASEL Gln/Gln genotype does not play an important role in the etiology of prostate cancer in the general population.

Original languageEnglish (US)
Pages (from-to)849-854
Number of pages6
JournalProstate
Volume67
Issue number8
DOIs
StatePublished - Jun 1 2007

Keywords

  • Inflammation
  • Non-steroidal anti-inflammatory drugs
  • Prostate cancer
  • RNASEL

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint Dive into the research topics of 'RNASEL Arg462Gln polymorphism and prostate cancer in PLCO'. Together they form a unique fingerprint.

Cite this